Article
Open access
Published: 13 December 2022

Gene augmentation prevents retinal degeneration in a CRISPR/Cas9-based mouse model of PRPF31 retinitis pigmentosa

Nature Communications volume 13, Article number: 7695 (2022) Cite this article

6906 Accesses
12 Citations
9 Altmetric
Metrics details

Subjects

Abstract

Mutations in PRPF31 cause autosomal dominant retinitis pigmentosa, an untreatable form of blindness. Gene therapy is a promising treatment for PRPF31-retinitis pigmentosa, however, there are currently no suitable animal models in which to develop AAV-mediated gene augmentation. Here we establish Prpf31 mutant mouse models using AAV-mediated CRISPR/Cas9 knockout, and characterize the resulting retinal degeneration phenotype. Mouse models with early-onset morphological and functional impairments like those in patients were established, providing new platforms in which to investigate pathogenetic mechanisms and develop therapeutic methods. AAV-mediated PRPF31 gene augmentation restored the retinal structure and function in a rapidly degenerating mouse model, demonstrating the first in vivo proof-of-concept for AAV-mediated gene therapy to treat PRPF31-retinitis pigmentosa. AAV-CRISPR/Cas9-PRPF31 knockout constructs also mediated efficient PRPF31 knockout in human and non-human primate retinal explants, laying a foundation for establishing non-human primate models using the method developed here.

Modeling PRPF31 retinitis pigmentosa using retinal pigment epithelium and organoids combined with gene augmentation rescue

Article Open access 16 August 2022

Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa

Article Open access 02 March 2020

Characterization of a novel Pde6b-deficient rat model of retinal degeneration and treatment with adeno-associated virus (AAV) gene therapy

Article 29 September 2022

Introduction

Retinitis pigmentosa (RP) is a group of inherited blinding disorders characterized by the degeneration of photoreceptors. Worldwide, RP affects between 1/2000 to 1/3500 people^1,2, and it is a major cause of blindness in younger patients^3,4,5. Currently, there is no efficient treatment for RP, making the disease a prime target for the development of novel therapeutics.

The typical onset symptom of RP is night blindness, followed by progressive constriction of the visual field, and culminating in the loss of visual acuity^6,7,8. Fundus imaging in patients shows a classic pattern of peripheral pigmentation, known as ‘bone-spicule pigmentation’, optic disk pallor, and attenuated retinal vessels⁹. Optical coherence tomography (OCT) shows that retinal structure is disrupted, with loss of the inner segment (IS)/outer segment (OS) junction followed by outer nuclear layer (ONL) thinning^10,11. Electroretinogram (ERG) recordings in patients often reveal the loss of retinal function, observed as a reduction in a- and b-wave amplitudes, which become non-detectable as the disease advances^12,13. Histopathologically, RP is characterized by primary degeneration of rods and secondary loss of cones. Alterations in the retinal pigmented epithelium (RPE) and retinal glia activation are also frequently observed¹⁴.

RP is a highly heterogenic group of diseases. Mutations in seven known splicing factors are found to be associated with autosomal dominant RP, including PRPF3¹⁵, PRPF4¹⁶, PRPF6¹⁷, PRPF8¹⁸, PRPF31¹⁹, SNRNP200²⁰, and RP9²¹. Mutations in PRPF31, pre-mRNA processing factor 31, are the most common among these, accounting for 6–11.1% of autosomal dominant RP²². PRPF31 is a highly conserved gene composed of 14 exons, 1 non-coding and 13 coding, located at chromosome 19q13.4. PRPF31 encodes a ubiquitous splicing factor, which facilitates the formation and stabilization of the U4/U6-U5 tri-snRNP (small nucleolar ribonucleoprotein) complex and plays essential roles in the mRNA splicing process^23,24. Homozygous Prpf31 knockout mice and zebrafish are embryonic lethal, indicating the essentiality of PRPF31^25,26. Intriguingly, despite ubiquitous expression, in humans, heterozygous mutations in PRPF31 result in retina-specific disease, for reasons that remain unclear.

PRPF31-RP shows incomplete penetrance as a result of varying levels of PRPF31 expressed by the unaffected allele, which is a phenomenon known as variant haploinsufficiency^1,27. Expressivity of the PRPF31 allele follows a continuous distribution in the general population, with the highest expression levels varying by around 5-fold relative to lowest expression levels²⁸. A PRPF31 heterozygous mutation carrier can be asymptomatic if the wild-type (WT) allele produces sufficient PRPF31 for normal retinal function, or can progress to blindness if remaining PRPF31 levels fall beneath a critical threshold. Due to non-penetrance, the prevalence of PRPF31 mutation carriers may have been underestimated.

Reported mutations in PRPF31 include frameshift, splice site, missense, and nonsense mutations, as well as replications and large-scale insertions or deletions, most of which are loss-of-function variants^22,29. Given the wide variety of loss-of-function PRPF31 variants, and the haploinsufficiency pathogenesis of the disease, gene augmentation represents the most widely applicable therapeutic approach. AAV-mediated gene therapy holds great promise to treat retinal inherited disease, as demonstrated by clinical trials showing the safety and efficacy of gene augmentation to treat LCA2, and subsequent FDA approval of Luxturna, the first clinically approved gene therapy for retinal disease³⁰. In a recent study, AAV-mediated PRPF31 augmentation was shown to improve cell morphology and restore critical functions in iPSC-derived PRPF31^−/+ cells³¹. Yet, to date, there are no suitable animal models in which to develop AAV-mediated PRPF31 gene therapies. Prpf31^A216P/⁺ and Prpf31^−/+ mouse models do not develop photoreceptor degeneration up to 18 months of age but show RPE changes that may be more characteristic of age-related macular degeneration than RP^25,32,33. Prpf31^+/− zebrafish models also do not show any RP phenotypes²⁶. Zebrafish models created through sublethal Prpf31 morpholino-mediated knockdown³⁴ and mutant PRPF31 expression³⁵ showed disrupted photoreceptor morphology and function. Knockdown of the PRPF31 homolog in Drosophila resulted in anophthalmia or microphthalmia with photoreceptor defects³⁶. However, these animals are not useful for preclinical AAV-PRPF31 testing because AAVs do not infect zebrafish or Drosophila efficiently.

The lack of a suitable disease model is a significant obstacle to the development of AAV-PRPF31 gene therapy. Here, we establish Prpf31 mutant RP mouse models through the delivery of AAV-CRISPR/Cas9 and characterize the resulting retinal degeneration caused by Prpf31-KO. We demonstrate the efficacy of AAV-mediated PRPF31 augmentation therapy in vivo and lay the foundation for creating NHP models of PRPF31-RP. These experiments provide a new platform for investigating the pathogenesis of PRPF31-RP and developing PRPF31 gene therapies and establish a path to accelerate the translation of AAV-mediated PRPF31 augmentation therapy to the clinic.

Results

Mouse gRNA screening

Streptococcus pyogenes Cas9 (SpCas9) and Staphylococcus aureus Cas9 (SaCas9) are widely used in vivo genome editing tools³⁷. SaCas9 is smaller than SpCas9, allowing for packaging of the Cas9 protein and gRNA into a single AAV vector. In order to create CRISPR/Cas9-based animal models of PRPF31-RP, gRNAs for SpCas9 and SaCas9 were designed to target early coding exons of Prpf31 in the mouse genome and were screened in vitro for efficiency (Supplementary Fig. 1 and Methods).

For SpCas9, gRNA2 was the most efficient (Supplementary Fig. 1a, b, and Methods). Co-transfection of SpCas9 and gRNA2-GFP plasmids resulted in 92.3 ± 0.58% editing of PRPF31 in GFP-positive HEK293 cells. For SaCas9, we tested the co-transfection of multiple gRNA constructs to increase efficiency. Co-transfection of SaCas9-gRNAg and SaCas9-gRNAh plasmids outperformed all other gRNA combinations and resulted in the lowest Prpf31 expression level (39.00 ± 16.09% relative to a GFP-transfected control) in NIH/3T3 cells (Supplementary Fig. 1e, f, and Methods). gRNAg targets mouse Prpf31 exon 2 and gRNAh targets exon 3.

Having validated a set of efficient gRNAs for use in SaCas9 and SpCas9 constructs, we then administered these constructs using 3 different injection routes to the mouse retina (Fig. 1). We tested subretinal injections (Fig. 1a), in which vector is injected under the retina, resulting in a retinal bubble, or bleb, and high rates of viral transduction in the outer retina. We also tested intravitreal injections (Fig. 1b), a method that is noninvasive to the retina, in which the vector is injected into the fluid filled cavity of the eye, after which vector diffuses across the inner surface of the retina. Lastly, we tested systemic injections (Fig. 1c), in which vector is injected through the facial vein and delivered to the retina via the vasculature, as well as to the entire body.

**Fig. 1: Illustration of AAV administration routes.**

Subretinal injection of Prpf31-KO vectors results in severe and rapid structural and functional degeneration in photoreceptors and RPE

Degeneration of photoreceptors and RPE in the outer retina is the most prominent pathological feature in RP patients. Therefore, we first aimed to achieve high expression levels of the KO vectors in the outer retina. We injected 7m8-CMV-SaCas9-U6-gRNAg/h (1.5 µl,1.01E + 12 vg/ml, ratio of gRNAg:gRNAh = 1:1) to the subretinal space of 4 to 5-week-old WT mice, a timepoint at which the retina has fully developed. PBS or a non-targeting (Nt) gRNA mock vector (7m8-CMV-SaCas9-Nt gRNA, 1.5 µl, 4.39 + E12 vg/ml) was injected in control eyes (Fig. 2a). The injection site was made at the temporal retina in a 1.5 µl volume, creating a bleb that covered approximately half of the retina. Eyes were imaged immediately after injection to record the location of the bleb (Supplementary Fig. 2). Five weeks post-injection (p.i.), the injected area of the KO retina was dissected out and genomic DNA was subjected to deep sequencing, revealing editing efficiencies of 57.29 ± 23.24% (Fig. 2b). The majority of mutant Prpf31 contained a ~184 bp deletion between the predicted cut sites (3 bp before the protospacer adjacent motif, PAM) of gRNAg and gRNAh, with the resulting coding sequence out-of-frame (Fig. 2c).

**Fig. 2: Subretinal injection of two *Prpf31*-KO vectors results in severe structural changes in outer retina.**

Fundoscopy was used to monitor the condition of retinas in vivo. Fundus imaging showed that 5 weeks (p.i.), the temporal retinas of KO mice were pale (Fig. 2d, white arrows), which overlapped with the location of the injection bleb (Supplementary Fig. 2). These pale patches of retina were not observed in PBS and mock-injected groups, confirming that retinal pallor was not a result of the injection procedure. The area of retinal pallor was expanded at 10 weeks (p.i.), and punctate black pigmentation formed, similar to the characteristic pigmentation observed in PRPF31-RP patients (Fig. 2d, black arrows). Attenuation of the retinal blood vessels, another funduscopic hallmark of RP, was also found in the injected area (Fig. 2d, red arrows).

OCT imaging showed significantly thinned temporal retina in KO eyes 5 weeks (p.i.), with loss of IS/OS, and reduction of ONL thickness. Additionally, the border between OS and the RPE layer became unclear, and migration of the RPE towards the inner retina was observed. Ten weeks (p.i.), dramatic retinal thinning with a complete loss of IS, OS and ONL was observed at the temporal retina. The RPE layer could not be identified. The nasal side (away from the injection site) of the retina also showed the disappearance of IS, OS, and ONL thinning at 10 weeks (p.i.), indicating that the area of retinal degeneration further expanded (Fig. 2e).

To further demonstrate structural changes in the KO eye at the histological level, we labelled HA-tagged Cas9 using anti-HA tag antibody. The expression pattern of Cas9 in the KO retina was the strongest in the outer retina under the injection bleb and decreased towards the edge of the bleb. Decreased anti-HA labeling, along with ONL thinning, was observed towards the center of the injection site due to the death of Prpf31-KO cells (Fig. 2f). The KO eyes showed notably reduced labeling of rhodopsin (RHO), peanut agglutinin lectin (PNA), and RPE65, indicating the loss of rods, cones, and RPE, corresponding to observations from OCT imaging (Fig. 2g). GFAP, a marker of Müller cell activation, was increased in KO retinas, indicating gliosis, a phenomenon often seen in degenerating retina (Fig. 2h).

To better understand the molecular mechanisms underlying retinal degeneration caused by Prpf31 KO, we quantified the mRNA expression of marker genes of temporal retina from KO and PBS-injected eyes 1, 2, 3, 4 weeks and 10 weeks (p.i.) (Fig. 3). Compared to PBS-injected eyes, expression of Prpf31 in KO eyes initially increased over the course of 3 weeks (p.i.), likely as a compensatory mechanism for the loss of PRPF31, which was also reported by Yin et al. in a zebrafish model³⁵, and then decreased significantly from 4 to 10 weeks (p.i.) (Fig. 3a–c). Markers of Müller cell activation, Vim and Gfap, steadily increased over the 10-week time period (Fig. 3a). Markers of apoptosis, Casp1, Casp4, and Casp12, initially increased, decreased briefly as Prpf31 expression transiently increased, and then increased dramatically from 4 to 10 weeks p.i (Fig. 3b). Expression of photoreceptor markers Rho, Opns1w, and Rpgr decreased slightly from 1–3 weeks (p.i.), and then decreased precipitously from 4 to 10 weeks (p.i.) as Prpf31 expression decreased (Fig. 3c).

**Fig. 3: Time course of differential gene expression in KO retina relative to PBS injected retina (n = 3). Expression of *Prpf31* is shown in all panels.**

ERG recording was used to evaluate the function of the retina. Scotopic and photopic a-, b- and c-waves were recorded, which reflect the response of photoreceptors, bipolar cells, and RPE, respectively. ERG recordings from eyes 5 weeks (p.i.) showed significantly reduced scotopic and photopic a- and b-wave responses in KO eyes across a wide range of stimulus intensities, indicating photoreceptor dysfunction (Fig. 4a–c). The c-wave amplitudes recorded from KO eyes were dramatically decreased, with prolonged implicit times compared to PBS and mock-injected groups, indicating compromised RPE function (Fig. 4d, e). At 10 weeks (p.i.), ERG responses of KO eyes were further impaired, showing almost no detectable a-, b-, or c-waves, indicating a dramatic loss of photoreceptor and RPE function (Fig. 4a–e).

**Fig. 4: Subretinal injection of two *Prpf31*-KO vectors results in severe functional changes in outer retina.**

Together, these data show that subretinal delivery of Prpf31-KO vectors results in substantial structural and functional impairment in the outer retina and leads to photoreceptor and RPE degeneration consistent with the typical clinical features of PRPF31-RP patients.

In order to test a single-vector system, we also subretinally injected 7m8-U6-gRNA2-CAG-GFP (0.6 µl, 2.13E + 12 vg/ml) in 4 to 5-week-old SpCas9-expressing mice (H11^Cas9 CRISPR/Cas9 knock-in mice, Jackson labs). GFP was co-expressed with gRNA to allow for in life monitoring of transgene expression. A control vector, 7m8-CAG-GFP (0.6 µl, 2.46E + 12 vg/ml), was injected in the contralateral eye (Supplementary Fig. 3a). At 5 weeks (p.i.), deep sequencing revealed a 14.92 ± 4.10% editing of Prpf31 DNA from whole retinas of KO eyes (Supplementary Fig. 3b). Over 50% of editing events resulted in the insertion of an adenosine at the predicted cut site of the gRNA2 target sequence, causing a frameshift mutation and generation of a premature stop codon (Supplementary Fig. 3c).

The results of Prpf31 KO in SpCas9-expressing mice were largely equivalent to those obtained using a 2-vector approach in WT mice. Structural changes, including significant reduction of retinal thickness, loss of photoreceptor and RPE markers, and impairment of retinal function, reflected by defective a-, b-, c- wave, were observed within 10 weeks (p.i.) (Supplementary Fig. 3d–h). Together, these results further validate those obtained using subretinal injections in WT mice and provide a single-vector system in which the effects of PRPF31 mutation can be investigated.

Intravitreal injection of Prpf31-KO vectors results in structural and functional changes primarily in the inner retina

Intravitreal injections are noninvasive to the retina and deliver AAV particles to the vitreous cavity of the eye, resulting in diffusion of vector across the expanse of the retina. With 2nd generation AAV capsids such as 7m8, intravitreally injected AAV particles first encounter cells in the inner retina, but can bypass structural barriers to transfect all retina layers³⁸. 7m8-U6-gRNA2-CAG-GFP (2 µl, 2.13E + 12 vg/ml) was delivered intravitreally to SpCas9-expressing mice aged 4 to 5 weeks. AAV 7m8-CAG-GFP (2 µl, 2.46E + 12 vg/ml) was delivered to the contralateral eye as a control (Fig. 5a). Deep sequencing of genomic DNA from whole retinas confirmed the editing of Prpf31 (3.73 ± 0.19%) 5 weeks (p.i.) (Fig. 5b). The addition of a single adenosine at the predicted cut site of gRNA2 target accounted for the majority of the mutant form of Prpf31 (Fig. 5c).

Five weeks (p.i.), expression of GFP was observed across the expanse of the retina (Supplementary Fig. 4a). Quantification of total retinal thickness from OCT imaging showed no statistically significant difference between control and KO groups while the thickness of the inner plexiform layer (IPL) was slightly but significantly reduced (Supplementary Fig. 4b). Fifteen weeks (p.i.), retina pallor was observed alongside the blood vessels in KO eyes (Fig. 5d, arrows and Supplementary Fig. 5), which overlapped with areas showing the highest GFP expression, suggesting the presence of retinal lesions occurring in the areas with highest gRNA expression. Also, at this later time point, a significant reduction in total retinal thickness was observed in KO eyes, with the greatest loss observed in the IPL. A disturbance of IS/OS junction was also noted in some KO eyes (Fig. 5d, red arrows). Imaging from retinal cross-sections showed that GFP was expressed in all retinal layers, with the strongest expression in the inner retina and Müller cells at 15 weeks (p.i.) KO eyes were marked by notable IPL and INL thinning, in agreement with OCT imaging (Fig. 5e). KO eyes showed a loss of the bipolar cell marker PKCα, shortened bipolar processes, as well as loss of the ganglion cell/amacrine cell marker PAX6 compared to control eyes (Fig. 5f).

ERG recording showed functional impairment of the KO retina. Five weeks (p.i.), scotopic a- and b-wave amplitudes of KO eyes were slightly reduced compared to control eyes (Supplementary Fig. 4c–e). Fifteen weeks (p.i.), b-wave amplitudes of the KO group decreased dramatically, while a-waves were moderately reduced (Fig. 5g, h), indicating the KO eyes had greater dysfunction in bipolar cells than in photoreceptors. While scotopic a-waves were reduced in KO eyes, no obvious reduction in rod and cone cell markers were observed between the two groups (Supplementary Fig. 6). Together, these data show that intravitreal delivery of Prpf31-KO vectors caused structural and functional impairment primarily in the inner retina of SpCas9-expressing mice.

Systemic injection of Prpf31-KO vectors results in abnormal development and high early mortality rate

Systemic delivery is noninvasive to the eye, and AAV92YF has been shown to achieve efficient transgene expression in the retina following systemic injection in neonates³⁹. We, therefore, delivered SaCas9 systemically using AAV92YF. AAV92YF-CMV-SaCas9-U6-gRNAg and AAV92YF-CMV-SaCas9-U6-gRNAh were mixed 1:1, and a 50 µl total volume at a titer of 1.35E + 13 vg/ml was delivered to P0 neonatal WT mice via facial vein injection (Fig. 6a). An equal volume of PBS or mock vector AAV92YF-CMV-SaCas9-Nt gRNA at a titer of 3.82E + 13 vg/ml was injected to litter mates as control. Systemic KO of Prpf31 resulted in pups with low body weight and high early mortality rate within 4 weeks (p.i.) (Fig. 6b–d). Evaluation of retinal structure and function by OCT and ERG was not possible because KO mice were too weak to survive anesthesia. Prpf31 editing was confirmed at the DNA and protein level. Liver tissue, which is efficiently targeted by systemic injections of AAV92YF, was collected. Genomic DNA was extracted and gRNAg/h target sites were PCR amplified. Prpf31 DNA from the KO group was truncated, at a length corresponding to the distance between gRNAg and gRNAh (184 bp) (Fig. 6e). Western blotting also showed significantly decreased PRPF31 protein in livers from the KO group (Fig. 6f–g). These results suggest that Prpf31 is essential for postnatal development and survival.

**Fig. 6: Systemic injection of Prpf31-KO vectors to P0 mice.**

Gene augmentation preserves histological structure and visual function in Prpf31 knockout retinas

Each of the 3 routes of injection tested – subretinal, intravitreal and systemic – resulted in genome editing in vivo. The severity of the disease and outcomes of gene editing were largely influenced by the injection route. Each of these models may be useful for the study of PRPF31. However, of the models tested, subretinal injections most closely resembled the pathophysiology of PRPF31-RP, with dramatic loss of photoreceptors and RPE, similar to the pathological changes observed in patients. This rapidly available model enables the testing of AAV-mediated gene augmentation for PRPF31 RP in vivo for the first time. We, therefore, tested a gene augmentation vector encoding human PRPF31 (hPRPF31) driven by a ubiquitous CAG promoter. hPRPF31 is not targeted by gRNAg/h due to a mismatch of the gRNA target sequence or the PAM sequence in the human genome. For each mouse, one eye was co-injected with KO vector 7m8-CMV-SaCas9-U6-gRNAg/h (0.75 µl, 1.01E + 12 vg/ml) and rescue vector 7m8-CAG-hPRPF31 (0.75 µl, 1.05E + 12 vg/ml). Vectors were mixed in a ratio of 7m8-CMV-SaCas9-U6-gRNAg: 7m8-CMV-SaCas9-U6-gRNAh: 7m8-CAG-hPRPF31 = 0.5:0.5:1. The contralateral control eye was injected with KO vector (0.75 µl) and PBS (0.75 µl) (Fig. 7a). The total volume of each subretinal injection was 1.5 µl/eye, and the injection sites were located at the temporal retina. The expression of hPRPF31 mRNA in the KO-Rescue eyes was confirmed at 10 weeks (p.i.) by qPCR using a pair of primers that bind to hPRPF31 specifically but not mouse Prpf31 (mPrpf31) (Supplementary Fig. 7). Deep sequencing of genomic DNA collected from whole retina at 10 weeks (p.i.) revealed that 38.02 ± 12.66% of mPrpf31 was modified in KO-Rescue eyes, while 24.08 ± 3.37% mPrpf31 was modified in the KO-PBS eyes (Fig. 7b). Following injection with the same dosage of Prpf31 KO vectors, KO-Rescue eyes had a higher percent of edited mPrpf31 compared to KO-PBS eyes, indicating that mPrpf31-KO cells were preserved in KO-Rescue retinas due to hPRPF31 augmentation. PRPF31 protein levels, quantified using automated Western blotting (Jess system, ProteinSimple), were reduced in KO-eyes, and were restored to normal levels in KO-Rescue eyes (Supplementary Fig. 8).

**Fig. 7: Gene augmentation preserves the structure of *Prpf31* knockout retinas.**

Fundoscopy in KO-rescue eyes revealed healthier retinas with reduced retinal pallor and pigmentation than the KO-PBS eyes (Fig. 7c and Supplementary Fig. 9). As previously observed, KO-PBS eyes were marked by temporal retinal pallor at 5 weeks (p.i.) At 7.5 weeks (p.i.), pigmentation formed at the area with retinal pallor and attenuation of blood vessels can be observed. And, 10 weeks (p.i.), the area of retinal pallor further expanded, with increased pigmentation. In contrast, no prominent area of retina pallor was observed in KO-Rescue eyes, and pigmentation was found only in a limited area surrounding the injection site, likely as a result of damage caused by subretinal injection.

OCT scanning showed maintained retinal thickness and preserved normal retinal structure in KO-Rescue eyes (Fig. 7d). In KO-PBS eyes, retinal thinning at the far temporal side (closest to the injection site) was apparent 5 weeks (p.i.), and at 10 weeks (p.i.), the thickness of temporal retina was dramatically decreased. In the affected area, IS and OS disappeared, the ONL was significantly thinned, and the border between RPE and OS was disturbed. In contrast, KO-Rescue retinas were significantly thicker, with only a minor reduction in retinal thickness from 5 weeks to 10 weeks (p.i.). Although in some individual KO-Rescue eyes, the border between OS/IS of temporal retina became less defined 5 weeks (p.i.), OS, IS, ONL, and RPE layers were preserved 10 weeks (p.i.). Heatmaps of retinal thickness generated from OCT volume scans of KO-PBS eyes illustrated significant retinal thinning at the temporal retina, while KO-Rescue eyes had improved thickness across the retina with damage limited to the injection site, corresponding to the results from fundoscopy and OCT B-scans (Fig. 7e). Immunolabeling of the HA-tagged SaCas9, photoreceptor and RPE maker genes confirmed the expression of KO vectors, preserved structure of the ONL and OS/IS and improved retinal morphology including survival of rods, cones, and RPE in KO-Rescue eyes (Fig. 7f).

Differential gene expression analysis was performed on mRNA from whole retina from KO eyes, KO-Rescue eyes, mock-injected eyes 10 weeks (p.i.), and WT uninjected litter mates (Fig. 7g). KO-Rescue eyes had higher expression levels of total PRPF31 (hPRPF31 and mPrpf31), lower expression levels of the cell death marker Casp12 and the glial cell activation markers Vim and Gfap, as well as higher expression levels of photoreceptor-specific gene markers (Rho for rods, Opn1sw and Pde6c for cones), compared to KO eyes, with overall gene expression levels similar to WT uninjected eyes. Collectively, differential gene expression analysis showed that hPRPF31 gene augmentation reduced cell death and gliosis, while preserving photoreceptor survival.

ERG recordings showed that KO-rescue eyes had improved rod and cone responses compared to KO-PBS eyes at all time points measured (Fig. 8a, c). KO-rescue eyes showed higher dark-adapted a-, and b- wave amplitudes than the KO-PBS eyes 5 weeks (p.i.) At 7.5 weeks (p.i.), a- and b-wave amplitudes of KO-rescue remained similar to amplitudes measured at 5 weeks (p.i.) while KO-PBS eyes showed a severe reduction of a- and b- wave amplitudes. At 10 weeks (p.i.), a-, and b- wave amplitudes of KO-rescue eyes remained significantly higher than those of KO-PBS eyes. The improvement of c-waves in the rescue group was also noted. From 5 to 10 weeks, the KO-rescue eyes had significantly higher c-wave amplitudes and shorter implicit times compared to KO-PBS eyes (Fig. 8b, d).

**Fig. 8: Gene augmentation preserves visual function of the *Prpf31* KO retina.**

KO of PRPF31 in primate retinal explants demonstrates the feasibility of establishing a NHP PRPF31-RP model

Mice are a leading preclinical model to test retinal gene therapies, due to ease of use, availability, and affordability. However, rodent eyes differ from human eyes in several key aspects, particularly, the lack of a fovea. NHPs are the model with eyes most similar to humans, and it is therefore of substantial interest to develop NHP models for preclinical development of gene therapies.

There is no available SaCas9 gRNA that targets early exons of both mouse and human/rhesus macaque PRPF31, due to cross-species sequence differences. We, therefore, designed gRNA constructs targeting human and rhesus macaque PRPF31. Co-transfection of SaCas9-gRNAa/c (44.33 ± 6.66% PRPF31 expression relative to control) and SaCas9-gRNAa/d (51.67 ± 7.57% PRPF31 expression relative to control) showed the highest knockout efficiency among the combinations tested. The combination of SaCas9-gRNAa/b also resulted in considerably reduced PRPF31 expression (56.67 ± 9.03% PRPF31 expression relative to control) (Supplementary Fig. 1c, d, and Methods).

We then packaged and tested the SaCas9-gRNAa/b/c/d vectors in rhesus and human ex vivo cultured retina, to establish proof-of-concept and demonstrate the feasibility of establishing a NHP model of PRPF31-RP using this system. Five-mm round retinal pieces were dissected from the center, middle, and peripheral retina, then incubated on a transmembrane, in a medium containing AAV particles (see Methods). AAV-CAG-GFP was applied to retinal explants as control for monitoring of the transgene expression during culturing, and CMV-SaCas9-gRNAa/c/d or a/b were applied to KO explants. AAV-7m8 or K9#12 was used as they have been shown to infect primate retinas with high efficiency^38,40,41. Fresh medium was replaced every second day, and retinal explants were harvested 9 days post AAV infection. Strong GFP expression was observed in the outer retina in cross-sections and flat-mounted retinal explants (Fig. 9a, b). Immunolabeling of anti-HA tag confirmed the successful expression of HA-tagged Cas9 in explants (Fig. 9b). Genomic DNA from the most highly infected areas of retinal explants were extracted and genomic regions containing gRNA targets were PCR amplified. The 7m8-SaCas9-gRNAa/b infected human explants showed a 12.76 ± 1.43% modification of PRPF31 quantified by deep sequencing, resulted in a 28 bp deletion between gRNAa and gRNAb (Fig. 9c). K9#12-SaCas9-gRNAa/c/d infected human and rhesus retinal explants and resulted in truncated DNA (Fig. 9d–f), with the size of the deletion corresponding to length of sequence between gRNAa and gRNAc (Supplementary Fig. 1c), suggesting that gRNAa and gRNAc were more efficient than gRNAd. The truncation of DNA between gRNAa and gRNAc was also verified by Sanger sequencing (Supplementary Fig. 10). Western blotting confirmed the expression of HA-tagged Cas9 protein in KO samples, and revealed the substantial reduction of PRPF31 protein in K9#12-SaCas9-gRNAa/c/d treated human retinal explants compared to control retina explants (Fig. 9g, h). These experiments strongly support the feasibility of developing NHP models of PRPF31-RP using the Cas9 vectors developed here.

**Fig. 9: KO of PRPF31 in NHP and human retinal explants demonstrates the feasibility of establishing a non-human primate PRPF31 RP model.**

Discussion

In this study, we used AAV-mediated CRISPR/Cas9 KO constructs delivered via subretinal, intravitreal, or systemic injection to create mouse models of PRPF31-RP, resulted in varying levels and rates of retinal dysfunction. Subretinal delivery of Prpf31 KO vectors resulted in obvious retinal pigmentation, severe retinal structural changes, and functional disruption within 10 weeks (p.i.). This is the first mouse model with a comparable phenotype to human PRPF31-RP patients, providing a new platform to investigate the pathogenetic mechanisms of PRPF31 and to evaluate treatment efficacy in vivo.

CRISPR/Cas9 edits a gene of interest through creation of a double-strand break in genomic DNA at the gRNA-targeted sequence. AAV-CRISPR/Cas9-based KO of Prpf31 in vivo may result in a mixture of cells with mutation in both alleles, mutation in a single allele, and non-edited wildtype cells. Mediated by AAV delivery, constitutive expression of Cas9 and/or gRNA in AAV-infected cells, over time, likely results in KO of both alleles. In contrast, in humans, PRPF31 mutations are present from the embryonic stage and cause disease through haploinsufficiency^1,27. The models developed here progress faster and have more severe retinopathy than what is observed in human patients, likely due to the complete KO of Prpf31 in AAV-infected retinal cells. However, Prpf31-KO in the mouse retina closely models the major structural and functional changes observed clinically in PRPF31-RP. Subretinal delivery of Prpf31 KO vectors resulted in retinal pigmentation and attenuated retinal vessels. The ONL was severly thinned, and ERG recordings revealed a reduction in a- and b-wave amplitudes over time. Alterations in the RPE and retinal glia activation were also observed.

Intravitreal delivery of Prpf31 KO vectors to the mouse retina using 7m8, an AAV2-based vector developed through directed evolution for its ability to deliver genes to the outer retina in mice, resulted mainly in changes in the inner retina and lesser changes in the outer retina. This corresponds to the transfection pattern of 7m8, which expresses most strongly in inner retinal cells from the vitreous, when packaged with a ubiquitous promoter³⁸. While outer retinal thinning is well-described in PRPF31-RP patients, there is little clinical data available on the condition of inner retina. Changes in inner retina in RP patients have largely been understood as a result of photoreceptor degeneration⁴². Histological analysis of human and mouse retina localize the expression of PRPF31 in inner retina as well as outer retina^43,44,45. Our study showed that inner retina including ganglion cells and bipolar cells were affected as a primary result of Prpf31 KO. It may be of interest to examine the inner retina when evaluating disease progression in PRPF31-RP patients, in order to determine the most effective gene therapy approach, and while considering new approaches for vision restoration such as optogenetic therapies, which hold great promise for late-stage RP patients but require RGCs to be in good condition⁴⁶.

The retina is a highly biosynthetically active tissue, and previous studies have suggested that the retina has a relatively higher demand for the functions of PRPF31, resulting in increased sensitivity to the reduction of PRPF31^35,47,48. This may explain why PRPF31 mutant carriers develop disease specific to the retina, as the remaining PRPF31 levels provided by the WT allele are sufficient for the normal function of other organs and tissues. Germline homozygous KO of Prpf31 in mice leads to abnormal embryonic development, while heterozygous KO resulted in no developmental abnormality^25,26. We performed systemic KO of Prpf31 in neonatal mice, resulting in stunted development and early death within 4 weeks (p.i.). This indicates that PRPF31 plays critical roles ubiquitously and that it is required for postnatal survival as well as embryonic development. Systemically delivered Prpf31 KO vectors in P0 mice may provide an animal model for studying the biological function of PRPF31 across tissues.

The gene augmentation rescue studies performed here were carried out using co-injection of KO and therapeutic vectors, in order to allow the earliest rescue possible, since retinal degeneration in this model progresses rapidly. In humans, the disease-causing mutation is present before birth and often diagnosed in adolescence. Further studies using sequential delivery of KO and rescue vectors on a more slowly degenerating background will be required to explore the potential of gene augmentation to reverse retinal degeneration with timing more similar to the course of human disease. To our knowledge this is the first use of in vivo CRISPR-KO and augmentation to simultaneously create and treat a model of retinal dystrophy. This approach may be useful for the rapid animal model creation of other homozygous lethal conditions. The expression of hPRPF31 was driven by a ubiquitous CAG promotor, as our study showed that a wide variety of retinal cells were affected by Prpf31 KO. The disease-causing cell type(s) of PRPF31-RP are most widely thought to be photoreceptors and/or RPE cells^25,32,33,49. Studies using cell type-specific promoters to drive KO and/or rescue may provide further insight into the role of Prpf31 in individual cell types. In addition, the development of a tissue-specific inducible Cre-Lox mouse line may be a useful approach to achieving more consistent and controlled ablation to reduce variability caused by retinal injections.

AAV-mediated hPRPF31 gene augmentation prevented the formation of retinal pigmentation, preserved normal retinal structure and function, including photoreceptors and RPE, and downregulated the expression of cell death and gliosis markers in the mPrpf31 KO retinas. This rescue was achieved in a disease model with more rapid progression and greater severity than patients, further demonstrating the promise of gene augmentation therapy for treating the loss of vision in PRPF31-RP patients.

There are immunological and structural differences between human and mouse eyes, including the presence of a fovea, larger total size, more viscous vitreous and a thicker inner limiting membrane on the retinal surface^50,51. NHP’s are the most biologically and anatomically similar to human, and therefore serve as a critical preclinical animal model. Germline editing may, in the future, be used to produce a PRPF31−/+ primate that more precisely models the haploinsufficiency of PRPF31 patients. However, the creation and maintenance of PRPF31 +/− primates would require years, and would be costly. In comparison, generating PRPF31 mutant NHP models by intraocular injection of AAV-mediated CRISPR/SaCas9 would be relatively achievable and rapidly available, allowing for larger-scale analysis. In this study, we investigated the possibility of creating a PRPF31-RP NHP model by delivering AAV-CRISPR/Cas9 PRPF31-KO vectors, similar to the constructs tested in mice, to rhesus and human retinal explants. Our results showed the successful expression of AAV-CRISPR/Cas9 constructs and KO of PRPF31 in rhesus and human retina, strongly supporting the feasibility of using the PRPF31-KO vectors developed here to establish a rapidly available in vivo NHP model of PRPF31-RP. However, retinal ex-vivo cultures do not contain the same structural barriers as in vivo models, and their survival window limited the use for long term studies, thus, an in vivo NHP PRPF31-RP model will be an important objective to pursue.

Collectively, these experiments further advance our understanding of PRPF31-RP and provide important in vivo mouse models, allowing further investigation of PRPF31 pathogenic mechanisms and development of treatments for PRPF31-RP in mice or future NHP models. This work also demonstrates in vivo proof-of-concept for AAV-PRPF31 gene augmentation for the first time. Together, these studies will accelerate therapeutic gene augmentation for PRPF31 to the clinic.

Methods

Animals

All procedures were performed in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. All animal experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee (IACUC).

Human tissue

All experiments were performed with approval and oversight from the University of Pittsburgh Committee for Oversight of Research and Clinical Training Involving Decedents (CORID, approval #927). Eyes from donors was obtained from the Center for Organ Recovery & Education (CORE). Organ recovery was performed by CORE and consent was obtained by CORE. Donor #1, 45-year-old male; donor #2, 32-year-old male, no history of retinal disease.

gRNA design and construction of AAV vectors

SpCas9 and SaCas9 were used in this study. gRNAs were designed to target early exons of Prpf31 in mouse, human, and rhesus macaque genome. For SpCas9, gRNA sequences were designed using the Synthego Knockout Guide Designer (https://design.synthego.com/#/) based on human and mouse genome, and then two high-ranking gRNA sequences (gRNA1 and gRNA2) that aligned to PRPF31 coding sequences of all three species were manually selected. The U6-gRNA1-gRNAscaffold and U6-gRNA2-gRNAscaffold fragments were synthesized (Integrated DNA Technologies) then cloned into pAAV-CAG-GFP vector³⁸ to create the pAAV-U6-gRNA-CAG-GFP construct.

gRNAs for SaCas9 were designed using CHOPCHOP⁵² and CRISPOR⁵³. gRNAa, gRNAb, gRNAc, gRNAd were designed to target human and rhesus macaque PRPF31 coding exons. gRNAg, gRNAh, and gRNAk were designed to target mouse Prpf31 coding exons. gRNA sequences were cloned into pX601-AAV-CMV_NLS-SaCas9-NLS-3xHA-bGHpA_U6_BsaI-sgRNA (Addgene, plasmid #61591). The unaltered Addgene plasmid #61591 with non-targeting gRNA to mPrpf31 was used as the mock Cas9 vector. All gRNA sequences are provided in Supplementary Table 2.

To construct the rescue vector pAAV-CAG-hPRPF31, the hPRPF31 coding sequence was obtained from NCBI (https://www.ncbi.nlm.nih.gov/nuccore/BC117389.1) and gene fragments were synthesized (Integrated DNA Technologies) and cloned into the pAAV-CAG backbone from the pAAV-CAG-GFP plasmid.

gRNA screening

For testing the efficiency of SpCas9 gRNA, HEK293 cells were co-transfected with the pX551-CMV-SpCas9 (Addgene, plasmid#107024) and pAAV-U6-gRNA1-CAG-GFP or pAAV-U6-gRNA2-CAG-GFP plasmid at a ratio of 1:1. Cells were harvested 72 h post-transfection and GFP positive cells were sorted using a FACSAria II Flow Cytometer (BD Bioscience). Genomic DNA from GFP-positive cells was extracted (Qiagen, DNeasy Blood & Tissue Kits), and the surrounding region of the gRNA target sites was PCR amplified and Sanger sequenced. Editing efficiency was analyzed by the ICE V1 CRISPR Analysis Tool (https://ice.synthego.com/#/). All primer sequences are provided in Supplemental Table 3.

The efficiency of SaCas9 gRNAs was tested by co-transfecting HEK293 cells (for human/ rhesus macaque gRNAs) and NIH/3T3 cells (for mouse gRNAs). Cells were harvested 72 h after transfection, and the expression levels of PRPF31 mRNA were quantified by qRT-PCR. All primer sequences are provided in Supplemental Table 4.

Of the two SpCas9 gRNAs tested, gRNA2, which targets mouse, human, and rhesus macaque PRPF31 exon 6, was the most efficient (Supplementary Fig. 1a, b, and methods). Co-transfection of SpCas9 and gRNA2-GFP plasmids resulted in 92.3 ± 0.58% editing of PRPF31 in GFP positive HEK293 cells.

SaCas9 is smaller than SpCas9, allowing for packaging of the Cas9 protein and gRNA into a single AAV vector. Three SaCas9 gRNAs that target mouse Prpf31 (mPrpf31) were individually tested. To achieve higher knock-out (KO) efficiency, multiple gRNA plasmids were transfected simultaneously. Co-transfection of SaCas9-gRNAg/h plasmids outperformed all other gRNA combinations and resulted in the lowest mPrpf31 expression level (39.00 ± 16.09% relative to an untransfected control) in NIH/3T3 cells. gRNAg targets mPrpf31 exon 2 and gRNAh targets exon 3.

There is no available SaCas9 gRNA that targets both mouse and human/ rhesus macaque PRPF31, due to cross-species sequence differences. For gRNAs targeting human/ rhesus macaque PRPF31, four gRNAs were tested: gRNAa (exon 2), gRNAb (exon 2), gRNAc (exon 4), and gRNAd (exon 5). To achieve higher knock-out (KO) efficiency, multiple gRNAs were used simultaneously. Co-transfection of SaCas9-gRNAa/c (44.33 ± 6.66% PRPF31 expression relative to control) and SaCas9-gRNAa/d (51.67 ± 7.57% PRPF31 expression relative to control) showed the highest knockout efficiency among the combinations tested. The combination of SaCas9-gRNAa/b also resulted in considerably reduced PRPF31 expression (56.67 ± 9.03% PRPF31 expression relative to control).

Cell culture and transfection

HEK293 cells (Cell Biolabs AAV293 cells # AAV-100) and NIH/3T3 cells (ATCC, #CRL-1658) were maintained in DMEM + Glutamax (Gibco) supplemented with 10% fetal bovine serum, 37 °C, 5% CO2. Transfection of HEK293 cells was performed according to the manufacturer’s protocol of DNA transfection reagent (JetPrime, #114-15) with 800 ng plasmid per well of a 12-well plate. Transfection of NIH/3T3 cells was performed with Lipofectamine 3000 (Thermo Fisher Scientific) with 1.5 μg plasmid per well of a 12-well plate. The medium was replaced 4–6 h after transfection. Cells were harvested 72 h post transfection.

AAV production

All constructs for AAV packaging were sequenced prior to packaging with Sanger sequencing. Inverted terminal repeats (ITRs) were validated through SmaI digest or deep sequencing (Azenta). AAV vectors were produced in AAV293 cells (Cell Biolabs # AAV-100) using a triple transfection method⁵⁴. Recombinant AAVs were purified by iodixanol gradient ultracentrifugation, buffer exchanged and concentrated with Amicon Ultra-15 Centrifugal Filter Units (#UFC8100) in PBS and were titered by quantitative PCR relative to a standard curve using ITR-binding primers⁵⁵.

Mice

C57BL/6 J mice and Cas9-expressing mice (H11^Cas9 CRISPR/Cas9 knock-in mice, B6J.129(Cg)-Igs2 < tm1.1(CAG-cas9*)Mmw > /J, Stock# 028239) were purchased from Jackson Laboratories. Mice were bred and housed in the animal facility of University of Pittsburgh under standard 12-h light/12-h dark conditions in rooms at a temperature of 65–75 °F (~18–23 °C) with 40–60% humidity.

Rhesus macaque

ID: M333-16, a 5-year-old female, was housed in the animal facility of the University of Pittsburgh under standard 12 h light/12-h dark conditions. The rhesus was euthanized for other experimental purposes and the eyes were a gift from William Stauffer’s Lab.

Intravenous injections

P0 neonatal pups were anesthetized on ice for 30–60 s, and transferred to an operating microscope⁵⁶. A total of 50 ul volume of AAV or PBS was injected through the temporal vein by a 31-gauge insulin syringe (Becton, Dickinson and Company). A successful injection was confirmed through observation that there was no obstruction from the needle, no bump under the pup’s skin and blanching of the vein. Following the injection, pups were warmed, recovered on a heating pad, and confirmed to be in good condition before being returned to their cages. Male and female pups were evenly distributed in each treatment group.

Intravitreal and subretinal injections

Mice age 4–5 weeks were anaesthetized by intraperitoneal injection of ketamine (80 mg/kg) and xylazine (8 mg/kg) and their pupils were dilated with 1% tropicamide (NDC 17478-102-12) followed by 2.5% phenylephrine (NDC 17478-201-02). Mice were placed under an operating microscope on a heating pad. To visualize the fundus, the mouse eye was covered by a 12 mm round cover slide (Fisher Scientific, 12CIR-2) after applying GenTeal lubricant eye gel (Alcon Laboratories). A guide hole was made with a 30-gauge needle (Medline) through the sclera behind the iris at a 45° angle towards the optic nerve. A micro-injection syringe with 33-gauge blunt-end needle (Hamilton) was then inserted into the hole and AAV was delivered to the vitreous body (for intravitreal injections), or the needle was used to pierce the temporal retina and inject AAV to the subretinal space (for subretinal injections) over a time course of 20 s. The syringe was held still and remained in the vitreous body for 20 s before slowly being removed from the mouse eye. Left eyes and right eyes were injected with different treatment methods to allow for internal controls. For each treatment group, left and right eyes were evenly distributed. Mice were allowed to recover on the heating pad before fully awakening, and then were returned to their cages. Both male and female mice were used in all experiments.

Fundoscopy

Eyes were imaged using a Phoenix Micron IV fundus camera system. Anesthesia and pupil dilation methods were the same as described above.

Optical coherence tomography (OCT)

OCT was performed using ultrahigh-resolution spectral domain optical coherence tomography (SD-OCT) (Bioptigen). Mice were anesthetized, pupils were dilated, and mice were positioned allowing for the optic nerve head (ONH) to appear in the center of the image. B-scans (5 frames averaged) and full field volume scans (300 frames) were captured. The thickness of retinal layers was measured from B-scan images using Image J, and the retinal thickness heatmaps were plotted from volume scans with Bioptigen InVivoVue 3.0.8 software.

Electroretinogram (ERG)

To evaluate retinal function, ERG recording was performed using a Celeris system (Diagnosys) in a dark room. Mice were dark adapted overnight (>8 h). Following anesthesia, mouse pupils were dilated, and eyes were lubricated by GenTeal lubricant eye gel before placing the electrodes onto the cornea. Mice were kept warm during ERG measurement with a 37 °C heating pad. Scotopic ERG responses to 0.001, 0.01, 0.1, 1, 10, 30 cd·s/m² white flashes were recorded and averaged from three sweeps per flash intensity with intervals of 10 to 30 s between each stimulus. Photopic ERG responses were recorded after a 10 min light-adaptation under 10 cd/m² background light. The intensities of the white flash stimulus were 0.01, 0.1, 1, 10, and 100 cd·s/m² on top of the 10 cd/m² background illumination. The a- and b-wave amplitudes were evaluated from the scotopic and photopic ERG recordings. The dark-adapted c-wave was recorded⁴⁹ using a single green flash at 64 cd/m² for 200 ms. Narrow and broad band filters were set to 0.1 and 30 Hz, respectively, and the recording time was 4000 ms. The amplitudes and implicit times of c-waves were evaluated.

Retinal explant culture

Eyes from rhesus macaque and human donors were dissected within 30 min after surgical removal. Eye cups were flat mounted and vitreous body was removed as much as possible. Central, mid-peripheral and peripheral retina was collected using a 5 mm biopsy punch (Fisher Scientific). Retinal tissue was carefully separated from RPE/choroid/sclera and transferred to cell culture inserts with 0.40 µm pore size (Thermo Fisher Scientific, #140640) with the photoreceptor side attached to the membrane. The retinal explants were cultured in Neurobasal Plus Medium (Gibco, A35829-01) supplemented with 2% B-27 (Gibco, A35828-01), 5 μg/ml Plasmocin prophylactic (InvivoGen, #ant-mpp) and Penicillin-streptomycin (Genesee scientific, PSL01-100ML) at 37 °C, 5% CO₂. The culture medium was changed after 24 h and ~40 µl of AAV suspension (for titers see Supplementary Table 3) was applied to the fresh medium. Medium was completely replaced every 48 h and 40 µl of AAV suspension was added to the fresh medium. GFP expression in the control retina was monitored using an ECHO Revolve flourescence microscope. After an incubation period of 10 days, retinal explants used for histological analysis were fixed with 4% paraformaldehyde (PFA). For those retinas used for DNA and protein extraction, the 1 mm edges of each explant were collected.

PCR and DNA deep sequencing

To determine editing efficiency in vivo, PCR fragments containing the targeted site of gRNA were amplified from gDNA using primers with partial Illumina adapter sequences (Supplementary Table 4). PCR products were then purified and sequenced with a 300-cycle paired-end run on a MiSeq Illumina sequencer. Sequencing was performed by Genewiz (https://www.genewiz.com/). For plots, Cutadapt2.10 was used to trim adapter sequences and eliminate all low-quality reads below the Phred score cut-off of 20⁵⁷, randomly downsampled to an equal number of reads from each biological replicate, and then combined to create a single file. Editing rates were analyzed and visualized using CRISPRESSO (https://crispresso.pinellolab.partners.org/).

Quantitative real time-polymerase chain reaction (qRT-PCR)

Total RNA was extracted from cells or tissues using an RNeasy mini kit or AllPrep DNA/RNA/Protein Mini Kit (Qiagen). Total RNA was reverse transcribed with the SuperScript™ IV First-Strand Synthesis System (Thermo Fisher Scientific) using random hexamers. qPCR amplification was performed using the FAST SYBR Green Master Mix (Thermo Fisher Scientific, #4385616) following the manufacturer’s recommendations. All primer sequences are provided in Supplemental Table 4.

Differential expression analysis

At 1, 2, 3, and 4 weeks (p.i.), total RNA was extracted from the temporal retina of KO and PBS-injected eyes. At 10 weeks (p.i.), total RNA was extracted from the whole retina of WT uninjected, PBS, Mock, KO, KO-Rescue eyes. Library preparation was performed using the Truseq RNA Library Prep Kit (Illumina) following the manufacturer’s instructions. Total RNA input was enriched for mRNA and fragmented. Random primers initiated first strand and second strand cDNA synthesis. Adenylation of 3’ ends was followed by adapter ligation and library amplification with indexing. A NextSeq 500 Illumina sequencer with high output 150 cycles was used to obtain 2 × 75 paired-end reads. We performed quality control of raw Fastq files with FastQC software, and Cutadapt2.10 was used to trim adapter sequences and eliminate all low-quality reads below the Phred score cut-off of 20. Salmon 1.1.0 was used to index and quantify transcripts using a mm10 Salmon index, which was produced with salmon index using a partial selective alignment method. Differential gene expression was analyzed using DESeq2 (2.11.40.5).

Western Blotting (WB)

Total protein from retinal tissue was extracted in RIPA buffer with 1x complete protease inhibitor cocktail (Roche, ref11697498001) or by the AllPrep DNA/RNA/Protein Mini Kit (Qiagen). For Figs. 5f and 8g, western blotting was performed following the method: Protein was quantified using the QuantiPro BCA Assay kit (Sigma-Aldrich) then mixed with sample buffer (Bio-Rad Laboratories) and denatured at 95 °C for 5 min. 20 μg of total protein was loaded and separated by an SDS-PAGE gel. Protein was then transferred to a PVDF membrane and blocked with 5% no-fat milk in TBST (Tris-buffered saline with Tween 20 detergent) for 1 h at room temperature (RT). The primary antibodies were incubated overnight at 4 °C in TBST with 1% no-fat milk. HRP-conjugated secondary antibodies were incubated for 1 h at RT. Antibodies used in this study are provided in Supplementary Table 5. Blots were developed using SuperSignal West Pico PLUS chemiluminescent substrate (Thermo Fisher Scientific). To re-probe membranes, the PVDF membranes were stripped by incubating at RT for 10–15 min in Restore plus western blot stripping buffer (Thermo Fisher Scientific). For Supplementary Fig. 8, PRPF31 expression levels were analyzed using a Jess ProteinSimple Western capillary system (BioTechne) using anti-PRPF31 primary antibody with HRP-conjugated secondary antibody and using in-capillary protein normalization. Analysis was performed using Compass software (BioTechne). A 12–230 kDa 25-capillary Jess separation kit (SM-W004) was used for protein separation. Samples were prepared following the manufacturer’s instructions using the EZ Standard Pack (PS-ST01EZ). Primary detection antibody anti-PRPF31 (Abcam, ab231782) was utilized at a concentration of 1:50. An anti-Rabbit detection module (DM-001) was used for secondary labeling. Protein normalization module DM-PN02 was used to perform sample normalization. Uncropped blots are presented in the Source Data file.

Immunohistochemistry (IHC)

Mice were euthanized and the superior side of each eye was labeled using a cauterizing pen. Eyes were enucleated and the anterior segment was removed. The eye cups were fixed in 4% paraformaldehyde on ice for 4–6 h and dehydrated sequentially in 5%, 10%, 20%, and 40% sucrose solutions in PBS at RT for at least 30 min each. Eye cups were embedded in a 1:1 mixture of 40% sucrose in PBS: OCT compound (Fisher Scientific) with the superior side facing upwards. 14 µm sections containing ONH were collected on glass slides and stored at −80 °C until immunolabeling was performed. Cryosections were rehydrated with PBS for 10 min and PBS plus 0.1% TritonX-100 (PBST) at RT for 30 min, and slides were blocked with 5% goat serum in PBST for 30 min at RT. Primary antibodies were incubated for 1–2 h at RT. Secondary antibodies were incubated for 1 h at RT. Antibodies used in this study are provided in Supplementary Table 6. Hoechst 33342 (Thermo Fisher Scientific, 1:5000 dilution) was applied for 12 min to stain nuclei. Images of the mid-temporal retina were taken using an Olympus FV1200 confocal microscope.

Statistical analysis

Two-way analysis of variance (ANOVA) was used to analyze the retinal thicknesses measured from OCT B-scan and the ERG a-, b- wave amplitudes. Two factors, treatment and distance from ONH (for OCT) or flash intensity (for ERG), were taken into consideration. The significance of treatment factor at each distance from ONH (for OCT) or each flash intensity (for ERG) was calculated by Sidak multiple comparisons test. Data from other assays were analyzed by the unpaired two-tailed t-test. Statistical analyses were performed using GraphPad Prism 9 (GraphPad Software, La Jolla, CA, USA). Data were presented as means ± SEMs. The criteria for significance were: not significant, P > .05; *P < .05; **P < .01; ***P < .001; ****P < .0001.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Deep sequencing and genome editing quantification data generated in this study have been deposited in Dryad (https://doi.org/10.5061/dryad.bcc2fqzf1). FastQ files are publicly available. Source data are provided with this paper.

Code availability

All code and tools used for data analysis have been previously published and are freely and publicly available (see Methods.) For SpCas9, gRNA sequences were designed using the Synthego Knockout Guide Designer (https://design.synthego.com/#/). gRNAs for SaCas9 were designed using CHOPCHOP⁵² and CRISPOR⁵³. For in vivo editing efficiency analysis, sequencing was performed by Genewiz (https://www.genewiz.com/). For plots, Cutadapt2.10 was used to trim adapter sequences⁵⁷. Editing rates were analyzed and visualized using CRISPRESSO⁵⁸. We performed quality control of raw Fastq files with FastQC software Version 0.11.9, and Cutadapt2.10 was used to trim adapter sequences and eliminate low-quality reads. Salmon 1.1.0⁵⁹ was used to index and quantify transcripts. Differential gene expression was analyzed using DESeq2⁶⁰ (2.11.40.5). For Jess SimpleWesterns, analysis was performed using Compass software v6.1.0 (BioTechne).

References

Rose, A. M. & Bhattacharya, S. S. Variant haploinsufficiency and phenotypic non-penetrance in PRPF31-associated retinitis pigmentosa. Clin. Genet. 90, 118–126 (2016).
Article CAS Google Scholar
Golovleva, I., Köhn, L., Burstedt, M., Daiger, S. & Sandgren, O. Mutation spectra in autosomal dominant and recessive retinitis pigmentosa in northern Sweden. Adv. Exp. Med. Biol. 664, 255–262 (2010).
Article CAS Google Scholar
Buch, H. et al. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study. Ophthalmology 111, 53–61 (2004).
Article Google Scholar
Pontikos, N. et al. Genetic basis of inherited retinal disease in a molecularly characterized cohort of more than 3000 families from the United Kingdom. Ophthalmology 127, 1384–1394 (2020).
Article Google Scholar
Al-Merjan, J. I., Pandova, M. G., Al-Ghanim, M., Al-Wayel, A. & Al-Mutairi, S. Registered blindness and low vision in Kuwait. Ophthalmic Epidemiol. 12, 251–257 (2005).
Article CAS Google Scholar
Hartong, D. T., Berson, E. L. & Dryja, T. P. Retinitis pigmentosa. Lancet 368, 1795–1809 (2006).
Article CAS Google Scholar
Martin-Merida, I. et al. Toward the mutational landscape of autosomal dominant retinitis pigmentosa: a comprehensive analysis of 258 spanish families. Invest Ophthalmol. Vis. Sci. 59, 2345–2354 (2018).
Article CAS Google Scholar
Hamel, C. Retinitis pigmentosa. Orphanet J. Rare Dis. 1, 40 (2006).
Article Google Scholar
Kiser, K. et al. Time course of disease progression of PRPF31-mediated retinitis pigmentosa. Am. J. Ophthalmol. 200, 76–84 (2019).
Article CAS Google Scholar
Utz, V. M., Beight, C. D., Marino, M. J., Hagstrom, S. A. & Traboulsi, E. I. Autosomal dominant retinitis pigmentosa secondary to pre-mRNA splicing-factor gene PRPF31 (RP11): review of disease mechanism and report of a family with a novel 3-base pair insertion. Ophthalmic Genet. 34, 183–188 (2013).
Article CAS Google Scholar
Bhatia, S., Goyal, S., Singh, I. R., Singh, D. & Vanita, V. A novel mutation in the PRPF31 in a North Indian adRP family with incomplete penetrance. Doc. Ophthalmol. 137, 103–119 (2018).
Article Google Scholar
Audo, I. et al. Prevalence and novelty of PRPF31 mutations in French autosomal dominant rod-cone dystrophy patients and a review of published reports. BMC Med. Genet. 11, 145 (2010).
Article Google Scholar
Ruberto, F. P. et al. Heterozygous deletions of noncoding parts of the PRPF31 gene cause retinitis pigmentosa via reduced gene expression. Mol. Vis. 27, 107–116 (2021).
CAS Google Scholar
Mordes, D. et al. Pre-mRNA splicing and retinitis pigmentosa. Mol. Vis. 12, 1259–1271 (2006).
CAS Google Scholar
Chakarova, C. F. et al. Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 11, 87–92 (2002).
Article CAS Google Scholar
Chen, X. et al. PRPF4 mutations cause autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 23, 2926–2939 (2014).
Article CAS Google Scholar
Tanackovic, G. et al. A missense mutation in PRPF6 causes impairment of pre-mRNA splicing and autosomal-dominant retinitis pigmentosa. Am. J. Hum. Genet. 88, 643–649 (2011).
Article CAS Google Scholar
McKie, A. B. et al. Mutations in the pre-mRNA splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa (RP13). Hum. Mol. Genet. 10, 1555–1562 (2001).
Article CAS Google Scholar
Vithana, E. N. et al. A human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11). Mol. Cell 8, 375–381 (2001).
Article CAS Google Scholar
Zhao, C. et al. Autosomal-dominant retinitis pigmentosa caused by a mutation in SNRNP200, a gene required for unwinding of U4/U6 snRNAs. Am. J. Hum. Genet. 85, 617–627 (2009).
Article CAS Google Scholar
Keen, T. J. et al. Mutations in a protein target of the Pim-1 kinase associated with the RP9 form of autosomal dominant retinitis pigmentosa. Eur. J. Hum. Genet. 10, 245–249 (2002).
Article CAS Google Scholar
Wheway, G., Douglas, A., Baralle, D. & Guillot, E. Mutation spectrum of PRPF31, genotype-phenotype correlation in retinitis pigmentosa, and opportunities for therapy. Exp. Eye Res. 192, 107950 (2020).
Article CAS Google Scholar
Liu, S. et al. Binding of the human Prp31 Nop domain to a composite RNA-protein platform in U4 snRNP. Science 316, 115–120 (2007).
Article ADS CAS Google Scholar
Makarova, O. V., Makarov, E. M., Liu, S., Vornlocher, H. P. & Lührmann, R. Protein 61K, encoded by a gene (PRPF31) linked to autosomal dominant retinitis pigmentosa, is required for U4/U6*U5 tri-snRNP formation and pre-mRNA splicing. Embo j. 21, 1148–1157 (2002).
Article CAS Google Scholar
Graziotto, J. J. et al. Three gene-targeted mouse models of RNA splicing factor RP show late-onset RPE and retinal degeneration. Invest Ophthalmol. Vis. Sci. 52, 190–198 (2011).
Article CAS Google Scholar
Li, J. et al. Prpf31 is essential for the survival and differentiation of retinal progenitor cells by modulating alternative splicing. Nucleic Acids Res. 49, 2027–2043 (2021).
Article CAS Google Scholar
Rose, A. M. et al. Expression of PRPF31 and TFPT: regulation in health and retinal disease. Hum. Mol. Genet. 21, 4126–4137 (2012).
Article CAS Google Scholar
Rio Frio, T., Civic, N., Ransijn, A., Beckmann, J. S. & Rivolta, C. Two trans-acting eQTLs modulate the penetrance of PRPF31 mutations. Hum. Mol. Genet. 17, 3154–3165 (2008).
Article Google Scholar
Xie, D. et al. Targeted next generation sequencing revealed novel prpf31 mutations in autosomal dominant retinitis pigmentosa. Genet Test. Mol. Biomark. 22, 425–432 (2018).
Article CAS Google Scholar
Maguire, A. M. et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N. Engl. J. Med. 358, 2240–2248 (2008).
Article CAS Google Scholar
Brydon, E. M. et al. AAV-mediated gene augmentation therapy restores critical functions in mutant prpf31(+/−) ipsc-derived rpe cells. Mol. Ther. Methods Clin. Dev. 15, 392–402 (2019).
Article CAS Google Scholar
Bujakowska, K. et al. Study of gene-targeted mouse models of splicing factor gene Prpf31 implicated in human autosomal dominant retinitis pigmentosa (RP). Invest Ophthalmol. Vis. Sci. 50, 5927–5933 (2009).
Article Google Scholar
Farkas, M. H. et al. Mutations in pre-mRNA processing factors 3, 8, and 31 cause dysfunction of the retinal pigment epithelium. Am. J. Pathol. 184, 2641–2652 (2014).
Article CAS Google Scholar
Linder, B. et al. Systemic splicing factor deficiency causes tissue-specific defects: a zebrafish model for retinitis pigmentosa. Hum. Mol. Genet. 20, 368–377 (2011).
Article CAS Google Scholar
Yin, J., Brocher, J., Fischer, U. & Winkler, C. Mutant Prpf31 causes pre-mRNA splicing defects and rod photoreceptor cell degeneration in a zebrafish model for Retinitis pigmentosa. Mol. Neurodegener. 6, 56 (2011).
Article CAS Google Scholar
Ray, P. et al. The splicing factor Prp31 is essential for photoreceptor development in Drosophila. Protein Cell 1, 267–274 (2010).
Article CAS Google Scholar
Knott, G. J. & Doudna, J. A. CRISPR-Cas guides the future of genetic engineering. Science 361, 866–869 (2018).
Article ADS CAS Google Scholar
Dalkara, D. et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl. Med. 5, 189ra176 (2013).
Article Google Scholar
Dalkara, D. et al. Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther. 19, 176–181 (2012).
Article CAS Google Scholar
Xi, Z., Öztürk, B. E., Johnson, M. E., Stauffer, W. R. & Byrne, L. C. Quantitative single-cell transcriptome-based ranking of engineered AAVs in human retinal explants. bioRxiv (2021).
Ozturk, B. E. et al. scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution. Elife 10, https://doi.org/10.7554/eLife.64175 (2021).
Milam, A. H., Li, Z. Y. & Fariss, R. N. Histopathology of the human retina in retinitis pigmentosa. Prog. Retin Eye Res. 17, 175–205 (1998).
CAS Google Scholar
Trifunovic, D. et al. A high-resolution RNA expression atlas of retinitis pigmentosa genes in human and mouse retinas. Invest Ophthalmol. Vis. Sci. 49, 2330–2336 (2008).
Article Google Scholar
Yuan, L., Kawada, M., Havlioglu, N., Tang, H. & Wu, J. Y. Mutations in PRPF31 inhibit pre-mRNA splicing of rhodopsin gene and cause apoptosis of retinal cells. J. Neurosci. 25, 748–757 (2005).
Article CAS Google Scholar
Wheway, G. et al. An siRNA-based functional genomics screen for the identification of regulators of ciliogenesis and ciliopathy genes. Nat. Cell Biol. 17, 1074–1087 (2015).
Article CAS Google Scholar
Sahel, J. A. et al. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat. Med. https://doi.org/10.1038/s41591-021-01351-4 (2021).
Cao, H. et al. Temporal and tissue specific regulation of RP-associated splicing factor genes PRPF3, PRPF31 and PRPC8–implications in the pathogenesis of RP. PLoS One 6, e15860 (2011).
Article ADS CAS Google Scholar
Vithana, E. N. et al. Expression of PRPF31 mRNA in patients with autosomal dominant retinitis pigmentosa: a molecular clue for incomplete penetrance? Invest Ophthalmol. Vis. Sci. 44, 4204–4209 (2003).
Article Google Scholar
Valdés-Sánchez, L. et al. Retinal pigment epithelium degeneration caused by aggregation of PRPF31 and the role of HSP70 family of proteins. Mol. Med. 26, 1 (2019).
Article Google Scholar
Dalkara, D. et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol. Ther. 17, 2096–2102 (2009).
Article CAS Google Scholar
Heegaard, S., Jensen, O. A. & Prause, J. U. Structure of the vitread face of the monkey optic disc (Macaca mulatta). SEM on frozen resin-cracked optic nerveheads supplemented by TEM and immunohistochemistry. Graefes Arch. Clin. Exp. Ophthalmol. 226, 377–383 (1988).
Article CAS Google Scholar
Labun, K. et al. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. Nucleic Acids Res. 47, W171–W174 (2019).
Article CAS Google Scholar
Concordet, J. P. & Haeussler, M. CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res. 46, W242–W245 (2018).
Article CAS Google Scholar
Grieger, J. C., Choi, V. W. & Samulski, R. J. Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1, 1412–1428 (2006).
Article CAS Google Scholar
Aurnhammer, C. et al. Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods 23, 18–28 (2012).
Article CAS Google Scholar
Gombash Lampe, S. E., Kaspar, B. K. & Foust, K. D. Intravenous injections in neonatal mice. J. Vis. Exp. e52037 (2014).
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. 17, 3 https://doi.org/10.14806/ej.17.1.200 (2011).
Pinello, L. et al. Analyzing CRISPR genome-editing experiments with CRISPResso. Nat. Biotechnol. 34, 695–697 (2016).
Article CAS Google Scholar
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417–419 (2017).
Article CAS Google Scholar
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Article Google Scholar

Download references

Acknowledgements

We are deeply grateful to the human donors and their families who made human retinal explant studies possible. We thank the Center for Organ Recovery and Education for facilitating the use of human retinal tissue. We appreciate help from the University of Pittsburgh Division of Laboratory Animal Resources (DLAR) for animal husbandry. The rhesus macaque eyes were a gift from William Stauffer’s Lab. We thank Anthony St. Leger and Nancy Zurowski for assistance with FACS sorting; Jeff Gross, Yibo Xi, and Fuyun Bian for guidance with ERG, OCT, WB and IHC; Esin Öztürk, Serhan Turunç, and Sara Jabalameli for advice on experiments and assistance with cell culture and AAV packaging; and Molly Johnson for advice on computational methods. Funding was provided by the NEI/NIH (UG3MH120094 to LB, and R01EY030991 to YC), Research to Prevent Blindness (LB; Career Development Award), Foundation Fighting Blindness (LB; Individual Investigator Award), the UPMC Immune Transplant and Therapy Center (LB), as well as through a scholarship from the China Scholarship Council, and the research fund from The Third Xiangya Hospital and Xiangya School of Medicine (ZX). RNA sequencing was performed at the University of Pittsburgh Genomics Research Core. We acknowledge support from NIH CORE Grant P30 EY08098 to the Department of Ophthalmology, from the Eye and Ear Foundation of Pittsburgh, and from an unrestricted grant from Research to Prevent Blindness. Biorender (www.biorender.com) was used to create figures.

Author information

Authors and Affiliations

Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, USA
Zhouhuan Xi, Abhishek Vats, José-Alain Sahel, Yuanyuan Chen & Leah C. Byrne
Eye Center of Xiangya Hospital, Hunan Key Laboratory of Ophthalmology, Central South University, Changsha, Hunan, China
Zhouhuan Xi
Department of Ophthalmology, Eye Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
Zhouhuan Xi
Department of Neurobiology, University of Pittsburgh, Pittsburgh, PA, USA
José-Alain Sahel & Leah C. Byrne
Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA
José-Alain Sahel & Leah C. Byrne

Authors

Zhouhuan Xi
View author publications
You can also search for this author in PubMed Google Scholar
Abhishek Vats
View author publications
You can also search for this author in PubMed Google Scholar
José-Alain Sahel
View author publications
You can also search for this author in PubMed Google Scholar
Yuanyuan Chen
View author publications
You can also search for this author in PubMed Google Scholar
Leah C. Byrne
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

Z.X. conceived, planned and executed experiments. Analyzed data. Wrote the manuscript. A.V. planned and executed experiments. J.A.S. conceived experiments, contributed materials, wrote the manuscript. Y.C. supervised work. Analyzed data. Wrote the manuscript. L.C.B. conceived, planned and executed experiments. Supervised work. Analyzed data. Wrote the manuscript.

Corresponding author

Correspondence to Leah C. Byrne.

Ethics declarations

Competing interests

J.A.S. is a co-founder of Avista Therapeutics and Vegavect. L.C.B. is an inventor on patent applications on AAV capsid variants and a co-founder of Avista Therapeutics and Vegavect. The remaining authors declare no competing interests.

Peer review

Peer review information

Nature Communications thanks Jean Bennett and the other anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Data 1

Reporting Summary

Source data

Source Data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Xi, Z., Vats, A., Sahel, JA. et al. Gene augmentation prevents retinal degeneration in a CRISPR/Cas9-based mouse model of PRPF31 retinitis pigmentosa. Nat Commun 13, 7695 (2022). https://doi.org/10.1038/s41467-022-35361-8

Download citation

Received: 05 March 2022
Accepted: 29 November 2022
Published: 13 December 2022
DOI: https://doi.org/10.1038/s41467-022-35361-8

This article is cited by

Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina
- Milan Gautam
- Antony Jozic
- Gaurav Sahay
Nature Communications (2023)